Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2020-03-18
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of pomalidomide when given
together with dexamethasone and filgrastim-sndz and to see how well they work in treating
patients with multiple myeloma that has returned or that does not respond to treatment.
Pomalidomide may stimulate or suppress the immune system in different ways and may stop
cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Colony-stimulating factors, such as
filgrastim-sndz, may increase the production of red and white blood cells and may help the
immune system recover from the side effects of pomalidomide and/or dexamethasone. Giving
pomalidomide together with dexamethasone and filgrastim-sndz may work better in treating
patients with multiple myeloma.